Literature DB >> 20937835

Peptidylarginine deiminase 2 suppresses inhibitory {kappa}B kinase activity in lipopolysaccharide-stimulated RAW 264.7 macrophages.

Hye Jeong Lee1, Myungsoo Joo, Rasul Abdolrasulnia, David G Young, Inyeong Choi, Lorraine B Ware, Timothy S Blackwell, Brian W Christman.   

Abstract

Peptidylarginine deiminases (PADs) are enzymes that convert arginine to citrulline in proteins. In this study, we examined PAD-mediated citrullination and its effect on pro-inflammatory activity in the macrophage cell line RAW 264.7. Citrullination of 45-65-kDa proteins was induced when cells were treated with lipopolysaccharide (LPS; 1 μg/ml). Protein citrullination was suppressed by the intracellular calcium chelator BAPTA/AM (30 μM). LPS treatment up-regulated COX-2 levels in cells. Interestingly, overexpressing PAD2 reduced LPS-mediated COX-2 up-regulation by 50%. PAD2 overexpression also reduced NF-κB activity, determined by NF-κB-driven luciferase activity. The effect of PAD2 on NF-κB activity was further examined by using HEK 293 cells transfected with NF-κB luciferase, IκB β/γ kinase (IKKβ/γ) subunits, and PAD2. IKKβ increased NF-κB activity, but this increase was markedly suppressed when PAD2 was present in cells. IKKβ-mediated NF-κB activation was further enhanced by IKKγ in the presence of calcium ionophore A23187. However, this stimulatory effect of IKKβ/γ was abolished by PAD2. Coimmunoprecipitation of cell lysates showed that IKKγ and PAD2 can coimmunoprecipitate in the presence of the Ca(2+) ionophore. IKKγ coimmunoprecipitated truncation mutants, PAD2(1-385) and PAD2(355-672). The substitution of Gln-358 (a putative ligand for Ca(2+) binding) with an Ala abolished coimmunoprecipitation. Conversely, PAD2 coimmunoprecipitated truncation mutants IKKγ(1-196) and IKKγ(197-419). In other experiments, treating RAW 264.7 cells with LPS induced citrullination in the immunoprecipitates of IKKγ. In vitro citrullination assay showed that incubation of purified PAD2 and IKKγ proteins in the presence of Ca(2+) citrullinated IKKγ. These results demonstrate that PAD2 interacts with IKKγ and suppresses NF-κB activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20937835      PMCID: PMC3000946          DOI: 10.1074/jbc.M110.170290

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Proteins that bind to IKKgamma (NEMO) and down-regulate the activation of NF-kappaB.

Authors:  Amde Selassie Shifera
Journal:  Biochem Biophys Res Commun       Date:  2010-05-10       Impact factor: 3.575

2.  Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes.

Authors:  Katsuhiko Nakashima; Teruki Hagiwara; Michiyuki Yamada
Journal:  J Biol Chem       Date:  2002-10-18       Impact factor: 5.157

3.  Ca2+/calmodulin-dependent protein phosphatase calcineurin mediates the expression of iNOS through IKK and NF-kappaB activity in LPS-stimulated mouse peritoneal macrophages and RAW 264.7 cells.

Authors:  YoungHee Kim; Ji Sun Moon; Kyoung Soon Lee; Sun Young Park; JaeHun Cheong; Ho Sung Kang; Hak Young Lee; Han Do Kim
Journal:  Biochem Biophys Res Commun       Date:  2004-02-13       Impact factor: 3.575

4.  Histone deimination antagonizes arginine methylation.

Authors:  Graeme L Cuthbert; Sylvain Daujat; Andrew W Snowden; Hediye Erdjument-Bromage; Teruki Hagiwara; Michiyuki Yamada; Robert Schneider; Philip D Gregory; Paul Tempst; Andrew J Bannister; Tony Kouzarides
Journal:  Cell       Date:  2004-09-03       Impact factor: 41.582

5.  Enhanced release of prostaglandin D2 during re-incubation of RAW 264.7 macrophage-like cells after treatment of both lipopolysaccharide and non-steroidal anti-inflammatory drugs.

Authors:  Yasuhito Tanaka; Makiko Takizawa; Shizunobu Igimi; Fumio Amano
Journal:  Biol Pharm Bull       Date:  2004-07       Impact factor: 2.233

6.  Structural basis for Ca(2+)-induced activation of human PAD4.

Authors:  Kyouhei Arita; Hiroshi Hashimoto; Toshiyuki Shimizu; Katsuhiko Nakashima; Michiyuki Yamada; Mamoru Sato
Journal:  Nat Struct Mol Biol       Date:  2004-07-11       Impact factor: 15.369

Review 7.  PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease.

Authors:  Erik R Vossenaar; Albert J W Zendman; Walther J van Venrooij; Ger J M Pruijn
Journal:  Bioessays       Date:  2003-11       Impact factor: 4.345

8.  Human PAD4 regulates histone arginine methylation levels via demethylimination.

Authors:  Yanming Wang; Joanna Wysocka; Joyce Sayegh; Young-Ho Lee; Julie R Perlin; Lauriebeth Leonelli; Lakshmi S Sonbuchner; Charles H McDonald; Richard G Cook; Yali Dou; Robert G Roeder; Steven Clarke; Michael R Stallcup; C David Allis; Scott A Coonrod
Journal:  Science       Date:  2004-09-02       Impact factor: 47.728

9.  Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.

Authors:  E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

10.  Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin.

Authors:  Erik R Vossenaar; Normand Després; Elvy Lapointe; Annemarie van der Heijden; Maximillian Lora; Tatsuo Senshu; Walther J van Venrooij; Henri A Ménard
Journal:  Arthritis Res Ther       Date:  2004-02-05       Impact factor: 5.156

View more
  18 in total

Review 1.  Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation.

Authors:  Erin E Witalison; Paul R Thompson; Lorne J Hofseth
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

Review 2.  Unconventional post-translational modifications in immunological signaling.

Authors:  Kerri A Mowen; Michael David
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

3.  Citrullination of NF-κB p65 promotes its nuclear localization and TLR-induced expression of IL-1β and TNFα.

Authors:  Bo Sun; Nishant Dwivedi; Tyler J Bechtel; Janet L Paulsen; Aaron Muth; Mandar Bawadekar; Gang Li; Paul R Thompson; Miriam A Shelef; Celia A Schiffer; Eranthie Weerapana; I-Cheng Ho
Journal:  Sci Immunol       Date:  2017-06-09

4.  A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22.

Authors:  Hui-Hsin Chang; Guang-Yaw Liu; Nishant Dwivedi; Bo Sun; Yuko Okamoto; Jennifer D Kinslow; Kevin D Deane; M Kristen Demoruelle; Jill M Norris; Paul R Thompson; Jeffrey A Sparks; Deepak A Rao; Elizabeth W Karlson; Hui-Chih Hung; V Michael Holers; I-Cheng Ho
Journal:  JCI Insight       Date:  2016-10-20

Review 5.  Peptidylarginine deiminases in citrullination, gene regulation, health and pathogenesis.

Authors:  Shu Wang; Yanming Wang
Journal:  Biochim Biophys Acta       Date:  2013-07-13

6.  Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis.

Authors:  Sunish Mohanan; Brian D Cherrington; Sachi Horibata; John L McElwee; Paul R Thompson; Scott A Coonrod
Journal:  Biochem Res Int       Date:  2012-09-16

7.  PADI2 is significantly associated with rheumatoid arthritis.

Authors:  Xiaotian Chang; Yifang Xia; Jihong Pan; Qingsong Meng; Yan Zhao; Xinfeng Yan
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240

8.  Vimentin is involved in peptidylarginine deiminase 2-induced apoptosis of activated Jurkat cells.

Authors:  Pei-Chen Hsu; Ya-Fan Liao; Chin-Li Lin; Wen-Hao Lin; Guang-Yaw Liu; Hui-Chih Hung
Journal:  Mol Cells       Date:  2014-05-22       Impact factor: 5.034

9.  Potential role for PAD2 in gene regulation in breast cancer cells.

Authors:  Brian D Cherrington; Xuesen Zhang; John L McElwee; Eric Morency; Lynne J Anguish; Scott A Coonrod
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

Review 10.  β cell ER stress and the implications for immunogenicity in type 1 diabetes.

Authors:  Meghan L Marré; Eddie A James; Jon D Piganelli
Journal:  Front Cell Dev Biol       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.